감염증 백신 시장 : 백신 유형별, 투여 경로별, 최종 사용자별, 유통 채널별 시장 예측(2026-2032년)

The Infectious Vaccines Market is projected to grow by USD 66.98 billion at a CAGR of 9.76% by 2032.

Infectious Vaccines Market Introduction

Infectious vaccines remain one of the highest-impact health technologies in global healthcare, preventing an estimated 3.5 million to 5 million deaths annually according to the World Health Organization. The infectious vaccines market is being shaped by sustained demand for pediatric immunization, adult booster programs, pandemic preparedness, travel vaccination, and protection against respiratory, vector-borne, and emerging infectious diseases.

Commercial momentum is supported by expanded use of mRNA, viral vector, recombinant protein, conjugate, live-attenuated, inactivated, and adjuvanted vaccine platforms. At the same time, public-sector procurement, Gavi-supported programs, national immunization schedules, and regulatory harmonization continue to influence access, pricing, and launch sequencing across developed and emerging markets.

Transformative Shifts in the Infectious Vaccines Landscape

The infectious vaccines landscape is shifting from episodic disease control toward continuous immunization readiness. COVID-19 accelerated regulatory collaboration, real-world safety monitoring, cold-chain investment, genomic surveillance, and platform-based vaccine development, creating faster pathways for vaccines targeting influenza, RSV, pneumococcal disease, HPV, malaria, dengue, tuberculosis, and future zoonotic threats.

Manufacturers are also adapting to combination vaccines, thermostable formulations, needle-free delivery research, and localized production. Demand is increasingly influenced by vaccine confidence, supply resilience, equitable access, antimicrobial resistance prevention, and the ability to demonstrate real-world effectiveness across infants, adolescents, adults, older adults, pregnant populations, travelers, and immunocompromised groups.

Cumulative Impact of Artificial Intelligence on Vaccine Innovation

Artificial intelligence is increasingly used across vaccine discovery, antigen selection, epitope mapping, immunogenicity prediction, clinical trial optimization, pharmacovigilance, and manufacturing analytics. AI-enabled models can accelerate candidate screening and support strain surveillance for pathogens with high mutation rates, including influenza, SARS-CoV-2, and other respiratory viruses.

The cumulative impact of AI is most visible when combined with high-quality genomic surveillance, electronic health records, immunization registries, and post-market safety databases. However, industry leaders must manage data bias, explainability, cybersecurity, validation standards, and regulatory acceptance to ensure AI improves vaccine speed without compromising safety, equity, or scientific rigor.

Key Regional Insights Across Asia-Pacific, North America, Latin America, Europe, Middle East, and Africa

Asia-Pacific is a high-priority region due to large birth cohorts, expanding domestic vaccine manufacturing, and rising government immunization investment, with China, India, Japan, South Korea, and Australia playing distinct roles in supply, R&D, regulatory strengthening, and advanced clinical adoption. North America remains a leading innovation and commercialization hub, supported by mature regulatory systems, adult immunization programs, strong biomedical research funding, and established CDC and Health Canada vaccination guidance.

Latin America continues to prioritize public procurement and regional disease control, with Brazil and Mexico central to demand for pediatric, HPV, influenza, pneumococcal, and outbreak-response vaccines. Europe benefits from centralized regulatory expertise, national immunization technical advisory groups, disease surveillance networks, and strong uptake of combination, travel, RSV, influenza, and HPV vaccines, while the Middle East is increasing investment in health security, preventive care, local manufacturing, and cold-chain infrastructure. Africa represents a critical access and impact region, where Gavi, UNICEF, WHO, Africa CDC, and national ministries support immunization against measles, polio, pneumococcal disease, rotavirus, HPV, malaria, yellow fever, cholera, and other high-burden infections.

Key Group Insights for ASEAN, GCC, European Union, BRICS, G7, and NATO

ASEAN markets are strengthening immunization coverage through public-sector programs, regional manufacturing partnerships, and expanded surveillance for dengue, influenza, measles, and respiratory pathogens. The GCC is investing in preventive healthcare, life sciences localization, medical countermeasure readiness, and pandemic preparedness, making infectious vaccines a strategic pillar of national health security.

The European Union provides regulatory scale through the European Medicines Agency and coordinated public health initiatives, while BRICS countries combine large population demand with growing vaccine production capacity, public procurement influence, and expanding disease surveillance systems. G7 nations remain central to vaccine R&D financing, advanced manufacturing, and global health funding, and NATO members increasingly frame vaccine resilience, stockpiling, continuity of supply, and medical countermeasures as part of biosecurity and civil preparedness.

Key Country Insights Across Major Infectious Vaccine Markets

The United States leads in vaccine biotechnology, federal procurement capacity, real-world evidence infrastructure, and adult immunization commercialization, while Canada emphasizes public health guidance, influenza prevention, equity-focused access, and provincial immunization delivery. Mexico and Brazil are important Latin American markets, with Brazil's public immunization infrastructure and local production capabilities supporting large-scale uptake, and Mexico maintaining demand through pediatric, influenza, HPV, and outbreak-prevention programs. In Europe, the United Kingdom, Germany, France, Italy, and Spain sustain demand through national immunization programs, aging populations, travel medicine, and adoption of RSV, pneumococcal, influenza, HPV, and combination vaccines; Russia maintains domestic vaccine capabilities and public-sector immunization priorities.

China and India are pivotal due to population scale, domestic production, regulatory modernization, and expanding innovation pipelines, with India also serving as a major global vaccine supplier for routine immunization programs. Japan prioritizes high-quality regulatory review, post-marketing safety, and aging-population vaccination, Australia maintains strong immunization registries and public health surveillance, and South Korea is advancing biomanufacturing, CDMO capacity, clinical research, and infectious disease preparedness.

Actionable Recommendations for Infectious Vaccine Industry Leaders

Industry leaders should prioritize diversified antigen portfolios, resilient supply chains, and platform technologies that can be rapidly adapted to outbreak, seasonal, and endemic disease needs. Organizations should align launch strategies with national immunization schedules, payer evidence requirements, real-world effectiveness data, and population-specific burden-of-disease analysis.

Executives should also invest in regional manufacturing partnerships, cold-chain optimization, pharmacovigilance automation, genomic surveillance integration, and vaccine confidence programs. Strategic differentiation will come from combination products, improved durability, simplified administration, thermostability, and robust evidence demonstrating reductions in hospitalizations, antimicrobial use, mortality, transmission, and overall healthcare costs.

Research Methodology for Infectious Vaccines Market Analysis

This executive summary is developed through secondary research using publicly available and verifiable sources, including WHO, CDC, UNICEF, Gavi, national immunization technical advisory groups, regulatory agencies, peer-reviewed literature, public health surveillance systems, and recognized global health databases. The analysis prioritizes evidence related to vaccine coverage, disease burden, platform innovation, procurement systems, safety monitoring, and regional health policy.

Insights are synthesized through data triangulation, trend mapping, technology assessment, and policy review. Qualitative interpretation is applied to compare regional demand drivers, manufacturing capabilities, regulatory dynamics, access barriers, immunization infrastructure, and competitive positioning within the infectious vaccines ecosystem, without relying on market sizing, share estimates, or forecasts.

Conclusion: Strategic Outlook for Infectious Vaccines

The infectious vaccines market is entering a more strategic phase defined by platform agility, AI-enabled discovery, public-private preparedness, genomic surveillance, and broader adult immunization. Long-term value will depend on reliable supply, regulatory trust, real-world evidence, vaccine confidence, and the ability to address both high-income booster markets and under-immunized populations.

Organizations that combine scientific innovation with equitable access, manufacturing resilience, transparent safety monitoring, and data-driven commercialization will be best positioned to capture growth opportunities while strengthening global protection against preventable infectious diseases.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Infectious Vaccines Market, by Vaccine Type

• 7.1. Conjugate
  • 7.1.1. Hib Conjugate
  • 7.1.2. Meningococcal Conjugate
  • 7.1.3. Pneumococcal Conjugate
• 7.2. Inactivated
  • 7.2.1. Hepatitis A
  • 7.2.2. Influenza
  • 7.2.3. Polio
  • 7.2.4. Rabies
• 7.3. Live Attenuated
  • 7.3.1. Influenza Laiv
  • 7.3.2. Measles
  • 7.3.3. Oral Polio
  • 7.3.4. Rubella
  • 7.3.5. Varicella
• 7.4. MRNA
  • 7.4.1. Lipid Nanoparticle MRNA
  • 7.4.2. Self-Amplifying MRNA
• 7.5. Subunit
  • 7.5.1. Protein Subunit
  • 7.5.2. Virus-Like Particle
• 7.6. Toxoid
  • 7.6.1. Diphtheria
  • 7.6.2. Pertussis
  • 7.6.3. Tetanus
• 7.7. Viral Vector
  • 7.7.1. Adenovirus
  • 7.7.2. MVA
  • 7.7.3. VSV

8. Infectious Vaccines Market, by Route Of Administration

• 8.1. Intradermal
• 8.2. Intramuscular
• 8.3. Intranasal
• 8.4. Oral
• 8.5. Subcutaneous

9. Infectious Vaccines Market, by End User

• 9.1. Clinics
  • 9.1.1. General Practice
  • 9.1.2. Specialty
• 9.2. Hospitals
  • 9.2.1. Private
  • 9.2.2. Public
• 9.3. Pharmacies
  • 9.3.1. Online
  • 9.3.2. Retail
• 9.4. Public Health Centers
  • 9.4.1. Rural
  • 9.4.2. Urban

10. Infectious Vaccines Market, by Distribution Channel

• 10.1. Government Agencies
  • 10.1.1. Local
  • 10.1.2. National
• 10.2. Hospital Pharmacies
  • 10.2.1. In-Hospital
  • 10.2.2. Outpatient
• 10.3. Online Pharmacies
  • 10.3.1. Direct
  • 10.3.2. Platform
• 10.4. Retail Pharmacies
  • 10.4.1. Chain
  • 10.4.2. Independent

11. Infectious Vaccines Market, by Region

• 11.1. Asia-Pacific
• 11.2. North America
• 11.3. Latin America
• 11.4. Europe
• 11.5. Middle East
• 11.6. Africa

12. Infectious Vaccines Market, by Group

• 12.1. ASEAN
• 12.2. GCC
• 12.3. European Union
• 12.4. BRICS
• 12.5. G7
• 12.6. NATO

13. Infectious Vaccines Market, by Country

• 13.1. United States
• 13.2. Canada
• 13.3. Mexico
• 13.4. Brazil
• 13.5. United Kingdom
• 13.6. Germany
• 13.7. France
• 13.8. Russia
• 13.9. Italy
• 13.10. Spain
• 13.11. China
• 13.12. India
• 13.13. Japan
• 13.14. Australia
• 13.15. South Korea

14. Competitive Landscape

• 14.1. Market Concentration Analysis, 2025
  • 14.1.1. Concentration Ratio (CR)
  • 14.1.2. Herfindahl Hirschman Index (HHI)
• 14.2. Recent Developments & Impact Analysis, 2025
• 14.3. Product Portfolio Analysis, 2025
• 14.4. Benchmarking Analysis, 2025

15. Company Profiles

• 15.1. Adimmune Corporation
• 15.2. AstraZeneca plc
• 15.3. Bavarian Nordic
• 15.4. Bharat Biotech
• 15.5. Biological E Limited
• 15.6. BioNTech SE
• 15.7. CanSino Biologics
• 15.8. China National Biotechnology Group
• 15.9. CSL Limited
• 15.10. Dynavax Technologies
• 15.11. Emergent BioSolutions, Inc.
• 15.12. GlaxoSmithKline plc
• 15.13. Haffkine Bio-Pharmaceutical Corporation
• 15.14. Inovio Pharmaceuticals
• 15.15. Johnson & Johnson
• 15.16. Merck & Co., Inc.
• 15.17. Mitsubishi Tanabe Pharma
• 15.18. Moderna, Inc.
• 15.19. Novavax, Inc.
• 15.20. Pfizer Inc.
• 15.21. Sanofi S.A.
• 15.22. Serum Institute of India
• 15.23. Sinovac Biotech Ltd.
• 15.24. Valneva SE
• 15.25. VBI Vaccines, Inc.